# Corcept Therapeutics Incorporated (CORT) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $81.93, market value $8.9 billion.

## Valuation
- **P/E (trailing): 182.1×** (5-yr avg 32.7×, 3-yr avg 39.3×). Corcept Therapeutics Incorporated trades at 182.1× trailing earnings, well above its own five-year average of 32.7×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 19.4×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 10.7×**. Each dollar of revenue is priced at 10.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 13.4×**. The shares trade at 13.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 1.2%** (5-yr avg 4.4%). Free cash flow equals 1.2% of the market value, below its five-year average of 4.4%, so the shares are pricier on cash than usual.
- **Earnings yield: 0.5%**. The inverse of the P/E: 0.5% of the price is earned each year.

## Profitability
- **Operating margin: 0.8%**. 0.8% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 13.1%**. 13.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 15.4%**. 15.4% on shareholders' equity is solid.
- **Return on invested capital: 1.0%**. Return on all capital, debt included, is 1.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 6.6%**. Each dollar of assets produces 6.6% of profit.

## Growth
- **Revenue growth (1 yr): 12.8%** (3-yr 23.7%/yr, 5-yr 16.6%/yr). Revenue grew 12.8% over the last year, against 16.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -33.3%** (3-yr -2.0%/yr, 5-yr -0.7%/yr). Earnings per share fell 33.3%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 5.7%/yr**. Free cash flow has compounded at 5.7% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Corcept Therapeutics Incorporated holds more cash than debt.
- **Current ratio: 2.92** (quick 2.92). Current assets cover the next year's liabilities 2.92 times.
- **Altman Z-score: 30.77**. A Z-score of 30.77 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Corcept Therapeutics Incorporated does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover Corcept Therapeutics Incorporated; the consensus is buy, with an average price target of $141.00 (+72% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 9.5%** (YTD 131.2%, 3-mo -28.7%). The shares are up 9.5% over twelve months including dividends.
- **From 52-week high: -35.2%** (185.9% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 23**. An RSI of 23 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 2.00** (volatility 83%). Beta of 2.00 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CORT · Page: https://foliofundamentals.com/stocks/cort

Not investment advice.